MORGAN STANLEY PLC/CALL/CELSIUS HLDGS/90/0.1/21.03.25 Share Price

Warrant

DE000MG4D252

Real-time Bid/Ask 09:04:22 03/07/2024 BST
0.42 EUR / 0.5 EUR +6.98% Intraday chart for MORGAN STANLEY PLC/CALL/CELSIUS HLDGS/90/0.1/21.03.25
1 month-67.42%
Date Price Change
02/07/24 0.43 -8.51%
01/07/24 0.47 +9.30%
28/06/24 0.43 -4.44%
27/06/24 0.45 +7.14%
26/06/24 0.42 -4.55%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 07:52 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying CELSIUS HOLDINGS, INC.
Issuer Morgan Stanley
WKN MG4D25
ISINDE000MG4D252
Date issued 16/05/2024
Strike 90 $
Maturity 21/03/2025 (262 Days)
Parity 10 : 1
Emission price 2.38
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.34
Lowest since issue 0.41
Spread 0.03
Spread %6.52%

Company Profile

Celsius Holdings, Inc. is engaged in the development, processing, marketing, sale, and distribution of functional energy drinks to a range of consumers. The Company's flagship asset, CELSIUS, is marketed as a fitness drink or supplement which, with exercise, is designed to accelerate metabolism and burn body fat while providing energy. This product line comes in two versions: a ready-to-drink form and an on-the-go powder form. The Company also offers a new CELSIUS Essentials line, available in 16-ounce cans. Celsius products are offered in retail channels across the United States, including conventional grocery, natural, convenience, fitness, mass market, vitamin specialty and e-commerce. Additionally, the Company's products are also offered in certain Canadian, European, Middle Eastern and Asia-Pacific markets. Its product's formulation includes ingredients and supplements such as green tea (EGCG), ginger (from the root), calcium, chromium, B vitamins and vitamin C.
Sector
-
More about the company

Consensus: Celsius Holdings, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
57.24 USD
Average target price
83.43 USD
Spread / Average Target
+45.76%
Consensus